This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Maraviroc, Celsentri, UK-427, 857, Maraviroc 1% gel
Description: Celsentri is a selective and reversible CCR5 coreceptor antagonist. Celsentri binds to a protein on the membrane of T-cells called CCR5. Once it does this, HIV cannot successfully bind with the surface of T-cells, thus preventing the virus from infecting healthy cells.
Selzentry was originally commercialized by Pfizer.
In April 2009, GlaxoSmithKline and Pfizer announced that the Companies have entered into an agreement to create a new HIV company (ViiV) focused solely on research, development and commercialisation of HIV medicines. Upon completion of the transaction, GSK will hold an 85% equity interest in the new company and Pfizer will hold 15% reflecting the value of their currently marketed products. To reflect the potential future performance of their respective HIV pipeline products, GSK and Pfizer have agreed a structure for their equity interests to be adjusted in the event that specified sales and regulatory milestones are achieved.
On November 3rd, 2009, GlaxoSmithKline (GSK) announced the official launch of ViiV Healthcare established by GSK and Pfizer (PFE). The transaction was completed on October 30th 2009.
Pfizer and IPM
In January 2008, the International Partnership for Microbicides (IPM) announced...See full deal structure in Biomedtracker
Partners: Pfizer Inc. International Partnership for Microbicides
Additional information available to subscribers only: